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Objective:Traditional neurosurgical practice calls for administration of peri-operative stress-
dose steroids for sellar-suprasellar masses undergoing operative treatment.This practice is
considered critical to prevent peri-operative complications associated with hypoadrenalism,
such as hypotension and circulatory collapse. However, stress-dose steroids complicate
the management of these patients. It has been our routine practice to use stress steroids
during surgery only if the patient has clinical or biochemical evidence of hypocortisolism
pre-operatively. We wanted to be certain that this practice was safe.
Methods: We present our retrospective analysis from a consecutive series of 114 oper-
ations in 109 patients with sellar and/or suprasellar tumors, the majority of whom were
managed without empirical stress-dose steroid coverage. Only patients who were hypoad-
renal pre-operatively or who had suffered apoplexy were given stress-dose coverage during
surgery. We screened for biochemical evidence of hypoadrenalism as a result of surgery
by measuring immediate post-operative AM serum cortisol levels.
Results:There were no adverse events related to the selective use of cortisol replacement
in this patient population.
Conclusion: Our experience demonstrates that selective use of corticosteroid replace-
ment is safe; it simplifies the management of the patients, and has advantages over empiric
“dogmatic” steroid coverage.
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INTRODUCTION
To prevent peri-operative complications associated with hypoad-
renalism, such as hypotension and circulatory collapse, adminis-
tration of peri-operative stress-dose glucocorticoids is traditional
in neurosurgical practice for sellar-suprasellar masses undergoing
operative treatment (Yeh and Chen, 1997). However, while caring
for post-operative Cushing’s disease patients who were profoundly
hypocortisolemic, we observed that hypotension, other than pos-
tural hypotension, was exceedingly rare. In fact, although the
patients suffered from general malaise and suffered anorexia, none
were in danger of death from cardiovascular collapse. Based on
this observation and supporting literature (Inder and Hunt, 2002;
Wentworth et al., 2008) we have abandoned the routine use of peri-
operative steroids for pituitary surgery for the last 10 years. The
policy proved safe clinically, but we wanted to analyze these data to
be sure that we were not being biased in our assessment. Therefore,
we instituted and maintained a database of our pituitary patients,
specifically examining the pre- and post-operative morning (AM)
cortisol levels and recording any peri-operative adverse events.
Abbreviations: CSF, cerebrospinal fluid; DI, diabetes insipidus; HPA, hypothalamus
pituitary adrenal; µg, micrograms.
PATIENTS AND METHODS
This study was approved by the local Institution Review Board.
From November, 2007 through February 2012, all patients
(n= 114) undergoing pituitary surgery at a single institution by
a single neurosurgeon (JCW) had the following information con-
currently recorded in a password secure database: age, surgery
type, date, and intraoperative complications such as CSF leak;
endocrine assessment including pre-operative AM cortisol and
post-operative cortisol; steroid replacement use; pathology; and
any adverse outcome (such as: infection, bleeding requiring trans-
fusion, symptomatic hypotension, unexpected neurological out-
come, diabetes insipidus (DI), hyper or hyponatremia, readmis-
sion within 90 days, cerebrospinal fluid leak requiring treatment,
any event requiring intensive care unit admission, or death). Pre
and post-op cortisol levels were measured by obtaining approx-
imately 3.0 ml serum in a SST transport container, refrigerated
and centrifuged. The Abbott ARCHITECT™ cortisol chemilumi-
nescent micro-particle immunoassay (CMIA) was used to acquire
µg/dl serum AM cortisol. Patients with a low pre-operative serum
AM cortisol level (<4µg/dl) were offered stress-dose steroid cov-
erage peri-operatively (50 mg hydrocortisone IV every 6 h for 36 h
and then oral replacement). Post-operative AM cortisol levels
were not obtained in patients receiving stress-dose coverage or
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in Cushing’s patients and thus these patients were not included in
the study.
The average patient age was 52.4± 12.0 years, with a
male:female ratio of 6:5. There were only three pediatric
patients. The series was dominated, as expected, by adenomas
(82 macroadenomas and 11 microadenomas). The single most
common surgical pathology in this series was a non-secreting
macroadenoma (67/85= 78.82%). There were 18 patients with
hypersecretion syndromes (15 acromegalic, and 3 hyperpro-
lactinemic). There were 15 Rathke’s cyst patients, two cranio-
pharyngiomas, one atypical teratoid/rhabdoid tumor, two autoim-
mune hypophysitis cases, and one case of tuberculous hypophysitis
(Figure 1).
SURGERY
All patients underwent a sublabial transseptal transsphenoidal or
an endoscopic transnasal approach to the sella with a wide bone
opening. A subcapsular dissection was performed in all cases
of adenomas, as described by Oldfield and Vortmeyer (2006).
An extended transsphenoidal approach was used in six cases
(two adenomas, one stalk adenoma, two craniopharyngiomas,
and one Rathke’s cyst) as previously described (Pluta et al.,
1999).
ANALYSIS OF THE HYPOTHALAMIC-PITUITARY-ADRENAL AXIS
Pre-operative assessment
Patients had AM cortisol tested pre-operatively as an assessment of
the Hypothalamic-Pituitary-Adrenal (HPA) axis. In two patients,
corticotropin-releasing hormone stimulation was also used. The
eight patients with Cushing’s disease were excluded, as these
patients do not receive intraoperative steroid replacement due
to their hypercortisolemia. Also excluded were 16 patients who
were on steroid treatment prior to surgery and therefore had no
pre-operative assessment.
FIGURE 1 | Pre- and Post-patient selection tumor pathologies.
Frontiers in Endocrinology | Pituitary Endocrinology March 2013 | Volume 4 | Article 30 | 2
Regan and Watson Pituitary surgery cortisol replacement
Four patients had missing AM serum cortisol pre-op. Therefore
we have pre-operative data on 86 surgical cases. Those patients
with a serum cortisol of <4µg/dl in our laboratory were con-
sidered adrenal impaired for the purpose of offering stress-dose
peri-operative steroid coverage.
Post-operative assessment
Post-operative day 1 AM cortisol was measured to determine
the integrity of the HPA axis. Again, the Cushing’s patients were
excluded (n= 8), as were patients who were maintained on exoge-
nous steroid replacement (n= 16) and the four that had missing
pre-operative AM cortisol.
Eighty-five non-Cushing’s patients with pituitary pathology
underwent 90 surgeries without stress-dose steroid coverage. Four
patients with missing pre-operative cortisol data were excluded,
leaving a total of 86 surgeries with sets of pre- and post-operative
AM serum cortisol samples.
The 16 patients who received peri-operative stress steroids
were mostly due to apoplexy (n= 13) who were already on stress
steroids, two patients with panhypopituitarism and one patient
with chronic obstructive pulmonary disease.
The average age of only the 86 patients included was
53.2± 14.7 years with a male to female ratio of 9 to 4.
STATISTICAL ANALYSIS
IMB SPSS 19.0 statistics software (IMP Corp., Armonk, NY, USA)
was used to perform statistical analysis. Difference were analyzed
using a one-sided t -test and a p-value of <0.05 was considered
significant.
RESULTS
Most post-surgical patients who were not treated with steroids
were found to have a significant rise in the AM cortisol, indica-
tive of a preserved HPA axis. By definition of the laboratories
in use by our hospital, a preserved HPA axis was considered
to be an AM serum cortisol of >4µg/dl. We chose this as
the base level. The mean pre-operative AM serum cortisol was
10.03µg/dl (SD± 5.62), and the mean post-operative AM cor-
tisol level was 23.1µg/dl (SD± 14.80, one-side t -test; P < 0.001)
(Figure 2). This difference can readily be seen in the individual lev-
els (Figure 3). Although there were 12 patients who saw a decrease
from pre-operative to post-operative AM cortisol levels (Figure 3)
only five patients failed to achieve appropriate post-op AM corti-
sol levels. These patients failed to distinguish themselves clinically
from those who did achieve appropriate post-op levels (i.e., not
symptomatic).
There were no patients in the series developed pituitary Addi-
son’s disease despite the five who failed to have an appropriate
post-op AM cortisol of >4µg/dl (Figure 3). Therefore screening
for HPA axis impairment (solely with a pre-op AM cortisol in the
vast majority of cases) was effective.
Five patients failed to mount a significant cortisol response
(Figure 3). Most of these patients received stress-dose steroids
post-operatively. All underwent a sublabial transseptal transsphe-
noidal approach to surgery. Three of these patients had relatively
low pre-operative AM cortisol levels of 4, 6.3, and 8.4. These
patients were diagnosed with micro prolactinoma, tuberculosis
FIGURE 2 | Mean pre- and post-operative serum cortisol levels (µg/dl)
in the study cohort of non-Cushing’s patients with pituitary pathology
that underwent surgeries without stress-dose steroid coverage. Four
patients with missing pre-operative cortisol data were excluded. Error bars
indicate standard deviation.
FIGURE 3 | Individual patient’s cortisol response to pituitary surgery:
note that most, but not all patients operated without stress steroids
show a significant rise in cortisol over baseline.
hypophysitis, and macro adenoma respectively. The remaining
two patients with insignificant cortisol response had low pre-op
cortisol of 3.6 and 2.5 and did not receive steroids by choice. Both
were in patients with non-secreting macro adenomas. Neither of
these uncovered patients had peri-operative hypotension or car-
diovascular instability. One of them did have delayed anorexia and
malaise and was readmitted for hyponatremia 1 week post-surgery.
At 2 weeks post-surgery, this patient’s AM cortisol was normal and
was asymptomatic without treatment.
ADVERSE EVENTS
There were no peri-operative deaths and no cases of cardiovascu-
lar collapse, symptomatic hypotension, or cardiovascular events
requiring intensive care. There were no patients who required a
blood transfusion or had a new neurological deficit.
www.frontiersin.org March 2013 | Volume 4 | Article 30 | 3
Regan and Watson Pituitary surgery cortisol replacement
There were adverse events in our series, but none that could be
explained by lack of steroid coverage. These included six patients
with a CSF leak, one in a delayed fashion (1 year). One of these six
patients received peri-operative steroids. There were nine cases of
DI, six of which were new post-operatively. Of the six cases of post-
operative DI two were adenomas, two craniopharyngiomas, and
two Rathke’s cysts. There was one case of post-operative culture-
negative meningitis treated with 10 days of intravenous antibiotics.
This patient had presented with pituitary apoplexy and did receive
peri-operative stress-dose steroids. There were five cases of symp-
tomatic normovolemic hyponatremia (presumed SIADH): one
had received steroids prior to operation and all patients recovered
within 3 days of readmission for hyponatremia. One patient with
acromegaly was diagnosed with a lower extremity deep venous
thrombosis and pulmonary embolism 8 days post-operative. She
had not received steroids.
DISCUSSION
Patients who had surgery for pituitary pathology did not need
peri-operative stress-dose steroid coverage: there were no adverse
events directly associated with performing pituitary surgery with-
out empirical steroid coverage. One of five patients requiring
readmission for hyponatremia was hypocortisolemic and it is
possible that lack of glucocorticoids contributed. However, one
of the five patients requiring readmission for hyponatremia was
put on peri-operative stress-dose steroids. Therefore, not only
was this policy safe, but it simplified patient management in all
cases, as it obviated the need to treat steroid-related complica-
tions [e.g., hyperglycemia with finger stick glucose monitoring
and sliding scale insulin (Al-Shoumer et al., 1995; Rajaratnam
et al., 2003), and gastric ulcers with pharmacologic gastric pro-
tectors, typically proton pump inhibitors] or to wean exogenous
steroids. Steroid naïveté further facilitates the endocrine assess-
ment, as the HPA axis may be examined at any time post-surgery
without obscuration by iatrogenic suppression of the axis. Addi-
tional benefits, beyond the scope of this paper, include avoiding
potential steroid-related deleterious effects on wound healing,
immunoresistance, behavior and sleep disturbances, and altered
bone metabolism (Peacey et al., 1997; Brown and Buie, 2001; Luk-
ert, 2006). Our policy was to treat with steroids if the patient
was symptomatic from hypocortisolemic pre-operatively, such
as was seen after apoplexy. Interestingly, the two patients with
low pre-operative AM cortisol that were not given glucocorti-
coids had no dire consequences. Of further note, the one case
of meningitis was in a patient who received stress-dose steroids
peri-operatively.
It is important to note that it has been shown that a sodium-
chloride containing fluid, like that of a saline injection, should
be used as an early intervention to combat acute Addison disease
crisis (Bouillon, 2006). The saline solution given to all patients
during surgery could have acted as a factor preventing adrenal
crisis in patients that did not receive peri-operative stress-dose
steroids. This fact could make giving stress-dose steroid coverage
to all patients even less necessary since patients are given saline
infusion during surgery.
Medical dogma may be perpetuated by the good intentions
of teachers and mentors in our hierarchical medical education
system. But tradition and historically based repetition of policies
may suffer from a lack of awareness of the origin of the policy
or subsequent evidence-based experiences. By example, the use of
empirical stress-dose glucocorticoids for pituitary surgery appears
to have developed in the following way: recommendations for
using high dose glucocorticoids in surgery began after two reports
in the late 1950s for patients with likely adrenal suppression (Fraser
et al., 1952; Lewis et al., 1953). Both reports describe the post-
operative death of patients who had been on high dose cortisone
prior to orthopedic surgery. The extrapolation of the experience of
these cases to empirical coverage for patients with macroadenomas
is ill-defined.
PITUITARY ADDISON’S
Pituitary surgeons are familiar with low cortisol states in our post-
operative Cushing’s disease patients. In these patients we observe
the symptoms of Addison’s disease such as anorexia and malaise.
In this setting, it is rare to see marked hypotension, though caution
is observed and usual anti-hypertensive medications are held. In
two non-Cushing’s patients from our series we observed the same
clinical manifestations of hypocortisolemia. These two refused
cortisol replacement (Figure 4); indeed one quickly regained
eucortisolemia. The clinical value of these observations is that cata-
strophic cardiovascular collapse is not a characteristic of pituitary
(secondary) Addison’s and allows for careful assessment rather
than empiric treatment (Glowniak and Loriaux, 1997).
In order to evaluate the integrity and reserve of the HPA axis
prior to surgical stress, we desire a simple, reliable measurement.
Many clinicians advocate the use of adrenocorticotropic hormone
(ACTH) stimulation, but it is costly, difficult to run and there is
controversy as to the best way to assess the axis (Aardal-Eriksson
et al., 1998; Klose et al., 2005; Ausiello et al., 2008; Pereira and
Bevan, 2008). We relied on the most simple of tests, the AM cor-
tisol, as a surrogate for the integrity of the HPA axis. The Abbott
ARCHITECT™ cortisol assay used in this study has shown a total
CV of <10% for serum samples between 3 and 35µg/dl and a
sensitivity of 20% CV in the lower levels (Abbott, 2009). Given the
difficulty and expense of more elaborate testing, using the AM cor-
tisol has been a solution in our practice and, based on this series,
appears adequate for the purposes of pre-operative planning for
pituitary surgery.
FIGURE 4 | AM serum cortisol levels of two patients with a low pre-op
cortisol that, by choice, did not receive steroids. Note that both
individuals had a poor cortisol response to surgery.
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Most patients mounted a considerable rise in their AM cortisol
(tripled) in response to pituitary surgery. However, this response
was varied from individual to individual, likely in part due to
the variable response of patients to surgery, pain, and “stress” in
general (Figure 3). However, we believe the post-operative AM
cortisol is important to document the preservation of the HPA
axis after surgery. Furthermore a similar observation was vali-
dated by a series of post-operative pituitary patients from Weil and
colleagues. They demonstrated a sensitivity (93%) and a positive
predictive value (99%) of the post-op cortisol to predict the preser-
vation of the HPA axis in 100 post-operative pituitary surgery
patients, compared to delayed cortrosyn stimulation testing, using
15µg/dl as the cut off value (Marko et al., 2009, 2010).
Our clinical series has shown that empirical use of stress-
dose glucocorticoids is not required for routine pituitary tumor
surgery. Physicians who choose not to empirically replace cortisol
should be able to recognize the signs and symptoms of hypoad-
renalism and may use post-op AM cortisol levels as a measure of
post-operative preservation of the HPA axis. Though there seems
to be no threat of adrenal crisis with selective use of stress-dose
glucocorticoids, our series is too small to be dogmatic in our con-
clusions and physicians should be able to recognize milder forms of
adrenal insufficiency that present as general malaise, appetite loss,
and fever. We reserve the right to treat for adrenal crises, should
the need arise, but that it is a relatively rare event and, as in our
experience with post-operative Cushing’s patients, mild enough to
be recognized and treated without catastrophic consequences. The
policy presented here appears safe, since there were no apparent
adverse events related to lack of empiric coverage; these data re-
enforced our larger clinical experience of normal cortisol response
in hundreds of pituitary patients over the last 10 years.
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